|
|
SPOT ON
|
|
Prevention of type 2 diabetes mellitus: what do results of studies really mean?
|
|
|
NEW ON THE MARKET
|
|
Dopamine-agonists pramipexole (SIFROL) and ropinirole (ADARTEL) for restless legs syndrome
|
|
|
REVIEW
|
|
Immunotherapy of allergic diseases (II)
|
|
|
THERAPY FROM A CRITICAL VIEWPOINT
|
|
Once again: Do long-acting beta-2 agonists increase complications of asthma?
|
|
|
a-t READERS' QUESTIONS AND COMMENTS
|
|
Statins for diabetic patients with end-stage renal disease?
|
|
|
IN BRIEF
|
|
Oral anticoagulants still first line antithrombotics in chronic atrial fibrillation
US: no approval of tibolone (LIVIELLA) for menopausal symptoms
Eyedrops: one is sufficient
|
|
|
CURRENT ADR NETWORK REPORT
|
|
Suicidality due to levofloxacin (TAVANIC) and other fluoroquinolones
|
|
|
SIDE EFFECTS
|
|
Infliximab (REMICADE): hepatosplenic gammadelta T-cell lymphoma
Malformations by angiotensin-converting enzyme inhibitors during the first trimenon
|
|